| Aug 6 |
Voyager Therapeutics GAAP EPS of -$0.18 beats by $0.23, revenue of $29.58M beats by $20.07M
|
| Aug 6 |
Voyager Therapeutics: Q2 Earnings Snapshot
|
| Aug 6 |
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
|
| Aug 5 |
Voyager Therapeutics Q2 2024 Earnings Preview
|
| Jul 30 |
Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
|
| Jul 4 |
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is definitely on the radar of institutional investors who own 49% of the company
|
| Jun 13 |
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
|
| Jun 13 |
Voyager Therapeutics appoints Nathan Jorgensen as CFO
|
| Jun 13 |
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
|
| Jun 5 |
Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
|
